Peter Ruane

Best Publications

• Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

  Jordan J. Feld;Ira M. Jacobson;Christophe Hézode;Tarik Asselah

  1332
  Citations

• Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

  Graham R. Foster;Nezam Afdhal;Stuart K. Roberts;Norbert Bräu

  1023
  Citations

• Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection

  Sharon Walmsley;Barry Bernstein;Martin King;José Arribas

  863
  Citations

• Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

  Bonaventura Clotet;Nicholas Bellos;Jean Michel Molina;David Cooper

  666
  Citations

• Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

  Susanna Naggie;Curtis Cooper;Michael Saag;Kimberly Workowski

  553
  Citations

• Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

  David L. Wyles;Peter J. Ruane;Mark S. Sulkowski;Douglas Dieterich

  525
  Citations

• Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

  Stefan Zeuzem;Graham R Foster;Stanley Wang;Armen Asatryan

  482
  Citations

• Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

  Kenneth H Mayer;Kenneth H Mayer;Jean-Michel Molina;Melanie A Thompson;Peter L Anderson

  430
  Citations

• Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients

  Edwin Dejesus;Daniel Berger;Martin Markowitz;Calvin Cohen

  392
  Citations

• Clinical targeting of HIV capsid protein with a long-acting small molecule.

  John O. Link;Martin S. Rhee;Winston C. Tse;Jim Zheng

  386
  Citations

• Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1: A Randomized Trial

  Mark S. Sulkowski;Joseph J. Eron;David Wyles;Roger Trinh

  382
  Citations

• Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.

  Peter J. Ruane;Edwin DeJesus;Daniel Berger;Martin Markowitz

  379
  Citations

• Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.

  Robert T Schooley;Peter Ruane;Robert A Myers;Gildon Beall

  374
  Citations

• Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.

  Unknown

  330
  Citations

• Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

  Ira M. Jacobson;Ira M. Jacobson;Eric Lawitz;Edward J. Gane;Bernard E. Willems

  291
  Citations

• Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19

  Unknown

  289
  Citations

• HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance

  Soo-Yon Rhee;Jonathan Taylor;W. Jeffrey Fessel;David Kaufman

  267
  Citations

• Risk Factors for Community-Associated Methicillin-Resistant Staphylococcus aureus Skin Infections among HIV-Positive Men Who Have Sex with Men

  Unknown

  247
  Citations

• Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial

  Joel E Gallant;Eric S Daar;François Raffi;Cynthia Brinson

  210
  Citations

• Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

  Jean-Michel Molina;Douglas Ward;Indira Brar;Anthony Mills

  209
  Citations